Palisade Bio Reports 100% Clinical Response in Phase 1b Ulcerative Colitis Cohort with Novel PDE4 Inhibitor, PALI-2108
PALI-2108 demonstrated to be safe and well tolerated with no serious adverse events (SAEs)
18 days ago